CACNA1E and Parkinson disease: Further studies with available TTCC or multiple Ca2+ channel targeting blockers and, if once available, Cav1.3- and Cav2.3-selective inhibitors will help to uncover the full therapeutic potential of Ca2+ channel inhibition for neuroprotection in PD.